Navigation Links
Seahorse XF96 Extracellular Flux Analyzer Wins Best New Product Award for DRUG DISCOVERY at 2009 Molecular Medicine Conference
Date:3/12/2009

BILLERICA, Mass., March 12 /PRNewswire/ -- Seahorse Bioscience, Inc., leader in the real-time measurement of cellular bioenergetics, announced today that the XF96 Extracellular Flux Analyzer, the first analytical instrument for the kinetic measure of mitochondrial oxygen consumption and cytoplasmic glycolysis in a 96-well microplate, was selected as the Best New Product for Drug Discovery Assays & Kits by researchers at the Molecular Medicine Tri-Conference in San Francisco.

"The XF96 Analyzer has revolutionized the way we approach toxicity screening," said Yvonne Will of Pfizer's Compound Safety Prediction Group, who spoke about mitochondrial toxicity at the conference and one of the first users of the XF96. "Since getting the high throughput capabilities of the XF96 Analyzer, we routinely generate 6 point cellular bioenergetic EC50's on our drug candidates - something that just wasn't possible before."

XF Analyzers enable researchers to simultaneously measure the two major energy-producing pathways of the cell in real-time, delivering easy-to-use, information-rich bioenergetic assays to study and develop treatments for obesity, diabetes, ageing and cancer, and to screen for mitochondrial toxicity.

The XF96 Analyzer offers the distinct advantage of making it possible to perform these complex bioenergetic assays in a 96-well microplate. XF Analyzers replace Clark-type electrodes, oxygen or pH sensitive dyes, and radiolabeled substrates.

"Prior to the introduction of our XF instruments the standard method for oxygen measurements was using a Clark electrode, invented in 1953, and a flask of millions of cells," stated Steve Chomicz, Seahorse VP Sales & Marketing. "The XF is the new standard and this award mirrors the positive response we experience everyday from researchers struggling to measure cellular bioenergetics. Seahorse and the XF development team are delighted with CHI's recognition of the value of the XF platform."

About Seahorse Bioscience

Seahorse XF instruments have become the new standard in cellular bioenergetic measurements. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, Seahorse is headquartered in Billerica, MA. For more information, please visit http://www.seahorsebio.com.

    Media Contact: Cynthia Egan
    Phone: 978.671.1610


'/>"/>
SOURCE Seahorse Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market
2. Extracellular protein sensitizes ovarian cancer cells to chemotherapy
3. Abaxis Launches The VetScan(R) HM5 a State-of-the-Art 5-Part Differential Veterinary Hematology Analyzer
4. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
5. New Gas Analyzer Measures Two Gases at Once!
6. Sysmex America Receives FDA Clearance for XE-5000(TM) Hematology Analyzer
7. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
8. PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer from Polymedco
9. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
10. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
11. CareAnalyzer From DST Health Solutions Helps Health Plans Improve Care Management and Quality for Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... 10, 2016 , ... Denver-based humanitarian aid organization, Saving Moses, ... toddlers. , The situation in Syria continues to worsen—deadly weapon explosions are increasing ... from disease. The situation is intensifying with winter coming and airstrikes increasing. ...
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman Company is ... As a means of expanding capabilities Flottman has added a G&K Vijuk ... code professional inserts (PIs) and patient package inserts (PPIs) that will marry with ...
(Date:12/9/2016)... ... 09, 2016 , ... Mediaplanet today announces distribution of the latest edition of ... sign up as an organ donor for the 123,000 people in the United States ... can save up to 8 saves through organ donation and enhance many others through ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West ... January 1, 2017. The name change aligns the entire company with its ... health care quality. , “We are very proud of the achievements associated with ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... County, a Property owned by an affiliate of Seavest, has won a prestigious ... Medicine Southern Chester County ambulatory care center (ACC) was named “Best New Development, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 2016 Research and Markets has announced the ... to their offering. ... The global travel vaccines market to grow at a CAGR ... the present scenario and the growth prospects of the global travel ... considers the revenue generated from the sales of various vaccines administered ...
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... , Dec. 8, 2016  The global biosurgery market ... during the forecast period of 2016 to 2021. The ... 2021 from USD 18.21 billion in 2016. The market ... incidences of sports related injuries and spinal problems, increasing ... need of effective blood loss management. In ...
Breaking Medicine Technology: